With this funding, Entvin plans to expand its AI capabilities & accelerate customer acquisition among mid-to-large pharmaceutical companies globally

Entvin AI, a startup founded by three IIT Bombay graduates, has officially launched out of beta and announced its funding from Y Combinator. The company provides specialised AI solutions for pharmaceutical and life sciences companies worldwide. Y Combinator is the world's most prestigious startup accelerator and Entvin AI has raised $500K in the first round of funding with a rigorous 0.1 per cent acceptance rate. With this funding, Entvin plans to expand its AI capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally.

The company, founded by Sanskar Jain, Hemant Phalak and Rishabh Arya, has developed an AI platform that streamlines the notoriously time-consuming, resource-intensive and complex FDA drug approval process, a market opportunity potentially worth billions as pharmaceutical companies worldwide seek to accelerate regulatory timelines and reduce compliance costs. The company reports early success with enterprise pilot customers, demonstrating that its AI solution can save hundreds of hours for regulatory and scientific teams while improving compliance accuracy, a critical factor in an industry where regulatory missteps can cost millions.

Sanskar Jain, Co-Founder and CEO, Entvin, highlighted: "We identified a significant opportunity to transform how life sciences companies navigate regulatory requirements. Regulatory professionals spend countless hours on documentation, compliance checks, and staying updated with constantly evolving FDA guidelines. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens."

Hemant Phalak, Co-Founder and CPO, emphasised, “At Entvin, our AI agents seamlessly integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn't just organize information - it actively identifies compliance gaps, automates repetitive documentation tasks, and provides regulatory teams with actionable insights in real time. This helps life science companies navigate the approval process with unprecedented efficiency while maintaining trust, reliability and seamless integration.

Rishabh Arya, Co-Founder and CTO, Entvin, explained, "We've developed an AI system that deeply understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2, ISO 2700."